Thirty-seven years ago, I stood in front of Andreas Gruentzig's poster at the American Heart Association's Scientific Session wondering how balloon inflation in a coronary artery would lead to anything good. I told him that it would never work, and I was wrong. However, the coronary artery did not quietly capitulate to this rude disruption, but fought back with a healing process that kept undoing the work of the balloon. The evolution of percutaneous coronary intervention has provided a laboratory for vascular biology research. With every advance in coronary intervention, we have produced new problems, which require new solutions, which produce new problems. Does the cycle ever end? Perhaps not, although the struggle has clearly been worth it, as millions of patients can testify. But, are we finished?
fewer stimuli for the phenomenon to occur, but there are millions of first-generation stents in our patients' coronary arteries now. What should the interventional approach be to obstructive in-stent restenotic lesions that may have neoatherosclerosis? Should very late restenosis be investigated with optical coherence tomography? Should interventional approaches be altered if lipid-rich core and thincap fibroatheroma are observed? Should aggressive antithrombotic or distal embolic measures be employed? Will aggressive medical therapy stabilize or reduce the progression of neoatherosclerosis? Will the disappearance of the bioresorbable stent eliminate neoatherosclerosis? Fortunately, most of our patients are doing fine, or if not, the problem they face most likely arises from parts of the coronary tree not previously stented rather than from the stented segment. Nonetheless, the occasional development of in-stent neoatherosclerosis after we thought we were out of the woods once again proves that fooling Mother Nature remains a work in progress.
